MRKR
Marker Therapeutics, Inc.
Biotechnology
Market Cap$24M
5Y Perf.-93.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MRKR vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+6.1%
MRKR vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MRKR | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $24M | $5.53B |
| Revenue (TTM) | $4M | $0.00 |
| Net Income (TTM) | $-12.16T | $-464M |
| Gross Margin | -137.3% | — |
| Operating Margin | -350.7% | — |
| Total Debt | $0.00 | $98K |
| Cash & Equiv. | $16.07T | $714M |
MRKR vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MRKR
IMVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Marker Therapeutics… (MRKR) | 100 | 6.3 | -93.7% |
| Immunovant, Inc. (IMVT) | 100 | 106.1 | +6.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MRKR vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IMVT leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Marker Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
MRKR
Marker Therapeutics, Inc.
The Income Pick
MRKR is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.27
- Rev growth -46.2%, EPS growth 33.6%, 3Y rev CAGR 0.3%
- Lower volatility, beta 1.27, current ratio 8.39x
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 173.6% 10Y total return vs MRKR's -98.1%
- -21.3% revenue growth vs MRKR's -46.2%
- 3.2% margin vs MRKR's -1000K%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IMVT | -21.3% revenue growth vs MRKR's -46.2% |
| Quality / Margins | IMVT | 3.2% margin vs MRKR's -1000K% |
| Stability / Safety | MRKR | Beta 1.27 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IMVT | +96.1% vs MRKR's +29.7% |
| Efficiency (ROA) | IMVT | -44.1% ROA vs MRKR's -255.1% |
MRKR vs IMVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
MRKR vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMRKRLAGGINGIMVT
IMVTImmunovant, Inc.
1leads
MRKRMarker Therapeutics, …
2leads
6 Total Categories
CATEGORYLEADERvs IMVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MRKR1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MRKR3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MRKR leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
MRKR and IMVT operate at a comparable scale, with $4M and $0 in trailing revenue.
| Metric | MRKRMarker Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $4M | $0 |
| EBITDAEarnings before interest/tax | -$12.89T | -$487M |
| Net IncomeAfter-tax profit | -$12.16T | -$464M |
| Free Cash FlowCash after capex | -$12.01T | -$423M |
| Gross MarginGross profit ÷ Revenue | -137.3% | — |
| Operating MarginEBIT ÷ Revenue | -3.5% | — |
| Net MarginNet income ÷ Revenue | -999999.0% | — |
| FCF MarginFCF ÷ Revenue | -999999.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -51.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +76.2% | +19.7% |
MRKR leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — MRKR and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MRKRMarker Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $24M | $5.5B |
| Enterprise ValueMkt cap + debt − cash | -$16.07T | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -1.82x | -9.97x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 6.78x | — |
| Price / BookPrice ÷ Book value/share | 0.00x | 5.83x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — MRKR and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MRKR leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
IMVT delivers a -47.1% return on equity — every $100 of shareholder capital generates $-47 in annual profit, vs $-3 for MRKR.
| Metric | MRKRMarker Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -2.9% | -47.1% |
| ROA (TTM)Return on assets | -2.6% | -44.1% |
| ROICReturn on invested capital | -0.0% | — |
| ROCEReturn on capital employed | -0.0% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | -$16.07T | -$714M |
| Cash & Equiv.Liquid assets | $16.07T | $714M |
| Total DebtShort + long-term debt | $0 | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
MRKR leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $613 for MRKR. Over the past 12 months, IMVT leads with a +96.1% total return vs MRKR's +29.7%. The 3-year compound annual growth rate (CAGR) favors IMVT at 12.1% vs MRKR's -4.8% — a key indicator of consistent wealth creation.
| Metric | MRKRMarker Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -6.5% | +5.1% |
| 1-Year ReturnPast 12 months | +29.7% | +96.1% |
| 3-Year ReturnCumulative with dividends | -13.8% | +40.9% |
| 5-Year ReturnCumulative with dividends | -93.9% | +62.4% |
| 10-Year ReturnCumulative with dividends | -98.1% | +173.6% |
| CAGR (3Y)Annualised 3-year return | -4.8% | +12.1% |
IMVT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MRKR and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MRKR is the less volatile stock with a 1.27 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs MRKR's 35.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MRKRMarker Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 1.37x |
| 52-Week HighHighest price in past year | $4.07 | $30.09 |
| 52-Week LowLowest price in past year | $0.81 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +35.4% | +90.5% |
| RSI (14)Momentum oscillator 0–100 | 47.7 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 125K | 1.4M |
Evenly matched — MRKR and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MRKRMarker Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $45.50 |
| # AnalystsCovering analysts | — | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MRKR leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). IMVT leads in 1 (Total Returns). 2 tied.
Best OverallMarker Therapeutics, Inc. (MRKR)Leads 2 of 6 categories
Loading custom metrics...
MRKR vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MRKR or IMVT a better buy right now?
Analysts rate Immunovant, Inc.
(IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MRKR or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +62. 4%, compared to -93. 9% for Marker Therapeutics, Inc. (MRKR). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus MRKR's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MRKR or IMVT?
By beta (market sensitivity over 5 years), Marker Therapeutics, Inc.
(MRKR) is the lower-risk stock at 1. 27β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 8% more volatile than MRKR relative to the S&P 500.
04Which is growing faster — MRKR or IMVT?
On earnings-per-share growth, the picture is similar: Marker Therapeutics, Inc.
grew EPS 33. 6% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MRKR or IMVT?
Immunovant, Inc.
(IMVT) is the more profitable company, earning 0. 0% net margin versus -999999. 0% for Marker Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus -350. 7% for MRKR. At the gross margin level — before operating expenses — IMVT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MRKR or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MRKR or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Immunovant, Inc.
(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+173. 6% 10Y return). Both have compounded well over 10 years (IMVT: +173. 6%, MRKR: -98. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MRKR and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.